Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells

Experimental Hematology

Volumn 33, Issue 2, 2005, Pages 159-164

  Konstantinidis, Kyriakos V ^a,b   Alici, Evren ^a,b   Aints, Alar ^a   Christensson, Birger ^c   Ljunggren, Hans Gustaf ^b   Dilber, M Sirac ^a,c  

^a Division of Hematology   (Sweden)

^b Center for Infectious Medicine   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; CELL COMPARTMENTALIZATION; CELL GROWTH; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; DRUG TARGETING; ENDOPLASMIC RETICULUM; EXTRACELLULAR SPACE; GENE CONSTRUCT; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GROWTH STIMULATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA PRIMERS; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; PLASMIDS; TRANSFECTION;

EID: 12844272200     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.11.003     Document Type: Article

References (35)

1. G. Trinchieri Biology of natural killer cells Adv Immunol 47 1989 187 376
2. E.R. Unanue Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response Immunol Rev 158 1997 11 25
3. C.A. Biron, K.B. Nguyen, G.C. Pien, L.P. Cousens, and T.P. Salazar-Mather Natural killer cells in antiviral defense: function and regulation by innate cytokines Annu Rev Immunol 17 1999 189 220
4. J.S. Orange, M.S. Fassett, L.A. Koopman, J.E. Boyson, and J.L. Strominger Viral evasion of natural killer cells Nat Immunol 3 2002 1006 1012
5. J. Wu, and L.L. Lanier Natural killer cells and cancer Adv Cancer Res 90 2003 127 156
6. R. Kiessling, E. Klein, and H. Wigzell "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype Eur J Immunol 5 1975 112 117
7. W.E. Seaman, M. Sleisenger, E. Eriksson, and G.C. Koo Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity J Immunol 138 1987 4539 4544
8. S. Kim, K. Iizuka, H.L. Aguila, I.L. Weissman, and W.M. Yokoyama In vivo natural killer cell activities revealed by natural killer cell-deficient mice Proc Natl Acad Sci U S A 97 2000 2731 2736
9. M.W. Lowdell Natural killer cells in haematopoietic stem cell transplantation Transfus Med 13 2003 399 404
10. P. Parham, and K.L. McQueen Alloreactive killer cells: hindrance and help for haematopoietic transplants Nat Rev Immunol 3 2003 108 122
11. L. Ruggeri, M. Capanni, and M. Casucci Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 94 1999 333 339
12. S.S. Farag, T.A. Fehniger, L. Ruggeri, A. Velardi, and M.A. Caligiuri Natural killer cell receptors: new biology and insights into the graft-vs-leukemia effect Blood 100 2002 1935 1947
13. A. Velardi, L. Ruggeri, A. Moretta, and L. Moretta NK cells: a lesson from mismatched hematopoietic transplantation Trends Immunol 23 2002 438 444
14. H. Guven, M. Gilljam, and B.J. Chambers Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy Leukemia 17 2003 1973 1980
15. B.R. Lauwerys, N. Garot, J.C. Renauld, and F.A. Houssiau Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18 J Immunol 165 2000 1847 1853
16. J. Parrish-Novak, S.R. Dillon, and A. Nelson Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function Nature 408 2000 57 63
17. M. Strengell, S. Matikainen, and J. Siren IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells J Immunol 170 2003 5464 5469
18. C.C. Liu, B. Perussia, and J.D. Young The emerging role of IL-15 in NK-cell development Immunol Today 21 2000 113 116
19. S.A. Rosenberg, M.T. Lotze, and L.M. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
20. R.C. Stein, V. Malkovska, and S. Morgan The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 Br J Cancer 63 1991 275 278
21. M.B. Atkins, M.T. Lotze, and J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
22. S. Chada, R. Ramesh, and A.M. Mhashilkar Cytokine- and chemokine-based gene therapy for cancer Curr Opin Mol Ther 5 2003 463 474
23. M.C. Panelli, R. White, and M. Foster Forecasting the cytokine storm following systemic interleukin (IL)-2 administration J Transl Med 2 2004 17
24. R.A. Maas, H.F. Dullens, and W. Den Otter Interleukin-2 in cancer treatment: disappointing or (still) promising? A review Cancer Immunol Immunother 36 1993 141 148
25. D.J. Weisdorf, P.M. Anderson, and B.R. Blazar Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - a phase I study Transplantation 55 1993 61 66
26. J.B. Ochoa, B. Curti, and A.B. Peitzman Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes J Natl Cancer Inst 84 1992 864 867
27. F.L. Glauser, G. DeBlois, and D. Bechard Cardiopulmonary toxicity of adoptive immunotherapy Am J Med Sci 296 1988 406 412
28. A. Ardizzoni, M. Bonavia, and M. Viale Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer Cancer 73 1994 1353 1360
29. J.S. Miller, J. Tessmer-Tuck, and N. Blake Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer Exp Hematol 25 1997 1140 1148
30. J.H. Gong, G. Maki, and H.G. Klingemann Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells Leukemia 8 1994 652 658
31. S. Nagashima, R. Mailliard, and Y. Kashii Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo Blood 91 1998 3850 3861
32. Y.K. Tam, G. Maki, and B. Miyagawa Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy Hum Gene Ther 10 1999 1359 1373
33. T.R. Malek, and A.L. Bayer Tolerance, not immunity, crucially depends on IL-2 Nat Rev Immunol 4 2004 665 674
34. C. Laker, C. Stocking, and U. Bergholz Autocrine stimulation after transfer of the granulocyte/macrophage colony-stimulating factor gene and autonomous growth are distinct but interdependent steps in the oncogenic pathway Proc Natl Acad Sci U S A 84 1987 8458 8462
35. T.M. Browder, J.S. Abrams, P.M. Wong, and A.W. Nienhuis Mechanism of autocrine stimulation in hematopoietic cells producing interleukin-3 after retrovirus-mediated gene transfer Mol Cell Biol 9 1989 204 213